$VCYT News

Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer

Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?

Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026

Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test

Veracyte Announces Receiving Of Coverage For Its Prosigna Breast Risk Of Recurrence Test For Its Technical Assessment Submission Through Palmetto GBA’s MolDX Program

Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026

Veracyte (NASDAQ:VCYT): Affordable Growth Backed by Strong Fundamentals

Veracyte (VCYT) Stock Still Looks Cheap As Its 107% Run Continues

Veracyte (VCYT) Could Be 22% Undervalued After New Decipher Phase III Data

Veracyte (VCYT) Is Down 9.0% After New Level 1B1 Decipher Prostate Data at ASTRO 2026

Could Veracyte (VCYT) Change Prostate Cancer Care With New Phase III Data?

Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

Veracyte To Present New Findings From Retrospective Ancillary Analysis Of Randomized Phase III NRG/RTOG 0815 Trial At 2026 ASTRO Annual Meeting

Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026

Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains?

Veracyte (NASDAQ:VCYT) Offers Affordable Growth Backed by Strong Health and Cash Flow

Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

Veracyte Acquires Convergent Genomics In $150M Deal, With Up To $30M Milestone Payments

Revvity to Acquire Human Cell Design to Boost Metabolic Discovery